Subscribe
Logo smallSearch

We treat hemato-oncology diseases almost fully in accordance with Western standards. However, there are also challenges

MedExpress Team

Piotr Wójcik

Published Feb. 13, 2024 11:51

We treat hemato-oncology diseases almost fully in accordance with Western standards. However, there are also challenges - Header image
Fot. Getty Images/iStockphoto
Access to treatment of hemato-oncology diseases needs further optimization. More reimbursement decisions are needed. With access to modern first-line drugs, patients get much better treatment outcomes and are much less burdened by the therapeutic process. This is also a real benefit for the system. These are the conclusions of the panel "Priorities in the area of hematooncological diseases," which took place as part of the Priorities in Health Care 2024 conference.

Although experts agree that in the care of patients struggling with hemato-oncologic diseases such as chronic lymphocytic leukemia and plasmocytic myeloma, we have a standard of treatment largely in line with Western standards, the results of treatment are still not entirely satisfactory. Data from the National Cancer Registry show that survival in Poland is still 10 percent lower than in Western European countries.

Meanwhile, we can talk about a breakthrough that has been made in the treatment of PBL. This is a therapy using two groups of drugs: Bruton's kinase inhibitors such as acalabrutinib, zanubrutinib and ibrutinib. All of these drugs are reimbursed in Poland. An alternative therapy is venetoclax in combination with obinutosumab, also reimbursed for first-line treatment.

- We are missing a single therapeutic regimen that combines two innovative drugs: ibrutinib and venetoclax. This is a very interesting regimen, because it combines two innovative drugs, and this therapy is interesting in that it is a time-limited therapy. Bruton's kinase inhibitor therapy lasts for many years. Most people will receive...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Najciekawsze oferty pracy (przewiń)